Cardio Diagnostics: PrecisionCHD,Epi+Gen CHD get pricing determinations from CMS

Cardio Diagnostics Holdings announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services CMS. This determination represents a crucial step toward securing Medicare reimbursement, enabling access to the Company’s affordable, innovative, and highly scalable blood tests aimed at improving the risk assessment, diagnosis, management and monitoring of coronary heart disease CHD for Medicare patients…”We are proud to reach this important milestone with CMS, bringing us closer to making our cutting-edge cardiovascular tests accessible to Medicare patients,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.